Clinical trial
MONET1-MOtesanib NSCLC Efficacy and Tolerability Study
NCT00460317 · Amgen, Industry · Terminated
Key facts
| NCT number | NCT00460317 |
|---|---|
| Title | MONET1-MOtesanib NSCLC Efficacy and Tolerability Study |
| Official title | A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-small Cell Lung Cancer. |
| Lead sponsor | Amgen, Industry |
| Collaborators | Takeda Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | AMG 706, placebo, paclitaxel, carboplatin |
| Enrollment | 1,450 |
| Start date | Jul 1, 2007 |
| Primary completion | Mar 1, 2011 |
| Completion | Aug 1, 2013 |
| First posted | Apr 13, 2007 |
| Last update posted | Sep 7, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: